Previous Article | Next Article 
Infection and Immunity, September 1999, p. 4360-4366, Vol. 67, No. 9
Department of Immunology, The Weizmann
Institute of Science, Rehovot, Israel
Received 24 February 1999/Returned for modification 15 April
1999/Accepted 2 June 1999
Schistosomiasis is the cause of a chronic debilitating disease
which accounts for significant mortality and morbidity every year,
especially in tropical and subtropical areas. An epitope derived from
the protective surface protein 9B-Ag of Schistosoma mansoni, designated 9B peptide-1, was previously showed to be protective in mice when conjugated to bovine serum albumin and administered subcutaneously in complete Freund's adjuvant. In this work, this protective peptide was expressed in the flagellin of a
Salmonella vaccine strain, and the
isolated recombinant flagella were used for immunization of mice.
Since during the invasion of the parasite into the host the
schistosomula migrate first to the lungs, the intranasal route of
administration was employed in order to halt the parasite at an early
stage of the infection. Such intranasal immunization with this
peptide expressed in flagellin, without the addition of
adjuvants, resulted in a significant humoral response and also led to
protection against challenge infection, manifested as a reduction of
the worm burden by an average of 42%.
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Intranasal Administration of Synthetic Recombinant Peptide-Based
Vaccine Protects Mice from Infection by Schistosoma
mansoni
*
Corresponding author. Mailing address: Department of
Immunology, The Weizmann Institute of Science, Rehovot, Israel
76100. Phone: 972-8-934-4018. Fax: 972-8-934-4141. E-mail:
liarnon{at}weizmann.weizmann.ac.il.
Infection and Immunity, September 1999, p. 4360-4366, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bates, J. T., Uematsu, S., Akira, S., Mizel, S. B.
(2009). Direct Stimulation of tlr5+/+ CD11c+ Cells Is Necessary for the Adjuvant Activity of Flagellin. J. Immunol.
182: 7539-7547
[Abstract] [Full Text] -
Weimer, E. T., Lu, H., Kock, N. D., Wozniak, D. J., Mizel, S. B.
(2009). A Fusion Protein Vaccine Containing OprF Epitope 8, OprI, and Type A and B Flagellins Promotes Enhanced Clearance of Nonmucoid Pseudomonas aeruginosa. Infect. Immun.
77: 2356-2366
[Abstract] [Full Text] -
Mizel, S. B., Graff, A. H., Sriranganathan, N., Ervin, S., Lees, C. J., Lively, M. O., Hantgan, R. R., Thomas, M. J., Wood, J., Bell, B.
(2009). Flagellin-F1-V Fusion Protein Is an Effective Plague Vaccine in Mice and Two Species of Nonhuman Primates. CVI
16: 21-28
[Abstract] [Full Text] -
Honko, A. N., Mizel, S. B.
(2004). Mucosal Administration of Flagellin Induces Innate Immunity in the Mouse Lung. Infect. Immun.
72: 6676-6679
[Abstract] [Full Text] -
Sbrogio-Almeida, M. E., Mosca, T., Massis, L. M., Abrahamsohn, I. A., Ferreira, L. C. S.
(2004). Host and Bacterial Factors Affecting Induction of Immune Responses to Flagellin Expressed by Attenuated Salmonella Vaccine Strains. Infect. Immun.
72: 2546-2555
[Abstract] [Full Text] -
Mizuki, M., Nakane, A., Sekikawa, K., Tagawa, Y.-i., Iwakura, Y.
(2002). Comparison of Host Resistance to Primary and Secondary Listeria monocytogenes Infections in Mice by Intranasal and Intravenous Routes. Infect. Immun.
70: 4805-4811
[Abstract] [Full Text] -
Ross, A. G. P., Sleigh, A. C., Li, Y., Davis, G. M., Williams, G. M., Jiang, Z., Feng, Z., McManus, D. P.
(2001). Schistosomiasis in the People's Republic of China: Prospects and Challenges for the 21st Century. Clin. Microbiol. Rev.
14: 270-295
[Abstract] [Full Text]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»